(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...
Explore the SHANK3 knockout model to enhance research in Phelan-McDermid syndrome and neurodevelopmental disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results